Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in ...

Petosemtamab (MCLA-158: EGFR x LGR5 Biclonics®): Solid Tumors LiGeR-HN1 phase 3 trial in 1L PD-L1+ r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC ...

Piper expects additional Phase II data on the combo in 2025 to “significantly de-risk” the Phase III LiGeR-HN1 study ... 2035 in head and neck squamous cell carcinoma alone.

Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...

LiGeR-HN1, a phase 3 trial, will evaluate the safety and efficacy ... Merus plans to enroll approximately 500 patients in the trial. Head and neck squamous cell carcinoma (HNSCC) describes a group of ...

r/m head and neck squamous cell carcinoma (HNSCC) and LiGeR-HN2 phase 3 trial in 2/3L r/m HNSCC enrolling – we expect both trials to be substantially enrolled by YE25; clinical update on phase 2 ...

The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.

The firm anticipates that forthcoming Phase II data in 2025 will further validate the efficacy of the drug, leading up to the Phase III LiGeR-HN1 study. The coverage initiation follows positive ...

against six state-of-the-art single cell alignment methods: Seurat v3, BBKNN, Scanorama, Harmony, LIGER, and BERMUDA. Compared to other approaches, CBA preserves the cluster separation in the original ...